EICHORCondition: Type 2 Diabetes Mellitus · Sponsor: AstraZeneca
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with T2DM and increased cardiovascular risk that is inadequately managed alone or on stable treatment with other background glucose-lowering medication(s).
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Birmingham, Alabama, United States | Not Yet Recruiting |
| Research Site | Mesa, Arizona, United States | Not Yet Recruiting |
| Research Site | Phoenix, Arizona, United States | Not Yet Recruiting |
| Research Site | Tempe, Arizona, United States | Not Yet Recruiting |
| Research Site | Covina, California, United States | Not Yet Recruiting |
| Research Site | Encinitas, California, United States | Not Yet Recruiting |
| Research Site | Garden Grove, California, United States | Not Yet Recruiting |
| Research Site | Loma Linda, California, United States | Not Yet Recruiting |
| Research Site | Long Beach, California, United States | Not Yet Recruiting |
| Research Site | Pomona, California, United States | Not Yet Recruiting |
| Research Site | Sacramento, California, United States | Not Yet Recruiting |
| Research Site | Bridgeport, Connecticut, United States | Not Yet Recruiting |
+ 189 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07662213